MMI-0100

CAT:
804-HY-P3412-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
MMI-0100 - image 1

MMI-0100

  • Description:

    MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2) . MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease[1].
  • UNSPSC:

    12352209
  • Target:

    MAPKAPK2 (MK2)
  • Type:

    Peptides
  • Related Pathways:

    MAPK/ERK Pathway
  • Applications:

    COVID-19-immunoregulation
  • Field of Research:

    Inflammation/Immunology
  • Assay Protocol:

    https://www.medchemexpress.com/mmi-0100.html
  • Purity:

    98.83
  • Solubility:

    H2O : 100 mg/mL (ultrasonic)
  • Smiles:

    OC(C=C1)=CC=C1C[C@H](N)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(C)C)C(NCC(N[C@@H](C(C)C)C(N[C@@H](C)C(N[C@@H](C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
  • Molecular Formula:

    C98H171N37O26
  • Molecular Weight:

    2283.64
  • References & Citations:

    [1]Akihito Muto, et al. Inhibition of Mitogen Activated Protein Kinase Activated Protein Kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. Vascul Pharmacol. Jan-Feb 2012;56 (1-2) :47-55.
  • Shipping Conditions:

    Blue Ice
  • Storage Conditions:

    -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)
  • Scientific Category:

    Peptides
  • Clinical Information:

    Phase 1
  • CAS Number:

    1039342-24-9